Selected Publications
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F.: Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer. under review Nature Communications : 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1.,2024.
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F: Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. Accepted with minor revisions Nature Communications : rs.3.rs-3854682. doi: 10.21203/rs.3.rs-3854682/v1,2024.
Fiona Simpkins, Dimitrios Nasioudis, Stephanie L. Wethington, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Drew A. Torigian, Dalia K. Omran, Diego Rodriguez, Simon Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Geoffrey Shapiro, Stephanie Gaillard, Robert L. Giuntoli II, Joyce F. Liu: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (Cohort A). ASCO presentation (ASCO Anual Meeting, June, 2024, Chicago, USA:
JCO Abstracts, June, 2024 : 2024.
Simpkins F, Nasioudis D, Wethington S, Martin L. Tanyi, J, Latif N, Torigian D, Omran D, Rodriguez D, Smith S, Dean E, Domchek S, Drapkin R, Shih I, Brown, E, Hwang W, Armstrong D, Gaillard S, Giuntoli R, Liu J: Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). ASCO, 2024, Annual Meeting. Chicago, IL : 2024.
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Lewis A, Mamidi S, Medvedev S, Anderton J, Tang J, Ferman B, Coats S, Wilkinson RW, Brown, E, Powell Jr. DJ, Simpkins F: A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression. Clinical Cancer Research : 30(8):1567-1581,2024.
Nasioudis D, Gysler S, Latif N, Cory L, Giuntoli RL 2nd, Kim SH, Simpkins F, Martin L, Ko EM: Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions. Gynecol Oncol : 180:1-5. doi: 10.1016/j.ygyno.2023.11.021,2024.
Nasioudis D, Wang X, Dhillon G, Latif N, Ko EM, Giuntoli RL 2nd, Gershenson D, Fader A, Carey M, Simpkins F.: Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. Int J Gynecol Cancer. : 33(12):1906-1912. doi: 10.1136/ijgc-2023-004745.,2023.
Nasioudis D, Gysler S, Latif NA, Ko EM, Cory L, F Simpkins, Kim SH: Utilization and outcomes of sentinel lymph node biopsy (SLNBX) for patients with cervical carcinoma; a multicenter database analysis Focused ORAL Presentation. International Gynecologic Cancer Society Meeting, Seoul : 2023.
Andriani L, Oh J, McMinn E, Gleason E, Koelper NC, Chittams J, Simpkins F, Ko EM.: Telehealth utilization in gynecologic oncology clinical trials. Gynecol Oncol. : 177:103-108. doi: 10.1016/j.ygyno.2023.08.011,2023.
Nasioudis D, Fernandez ML, Wong N, Powell DJ Jr, Mills GB, Westin S, Fader AN, Carey MS, Simpkins F.: The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecol Oncol. : 177:86-94. doi: 10.1016/j.ygyno.2023.08.007,2023.
Academic Contact Information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia,
PA
19104
Phone: 215-662-3318
Patient appointments: 800-789-7366